Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-22-000074
Filing Date
2022-08-11
Accepted
2022-08-11 08:30:44
Documents
6
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 6-K q22022form6-k.htm 6-K 23027
2 EX-99.1 2022 SECOND QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsjune302022.htm EX-99.1 387020
3 EX-99.2 2022 SECOND QUARTER MD&A ex992-q22022mda.htm EX-99.2 241817
4 EX-99.3 Q2 2022 CERTIFICATION CEO ex993-q22022certificationx.htm EX-99.3 14749
5 EX-99.4 Q2 2022 CERTIFICATION CFO ex994-q22022certificationx.htm EX-99.4 14646
6 oncolyticslogotaglinebluea.jpg GRAPHIC 355294
  Complete submission text file 0001129928-22-000074.txt   1121675
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 221153835
SIC: 2834 Pharmaceutical Preparations